KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.48
+0.00 (+0.52%)
Open$0.48
Previous Close$0.48
Day High$0.49
Day Low$0.48
52W High$2.06
52W Low$0.28
Volume—
Avg Volume292.0K
Market Cap16.93M
P/E Ratio—
EPS$-1.98
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,502.5% upside
Current
$0.48
$0.48
Target
$26.92
$26.92
$19.73
$26.92 avg
$29.00
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 437.7K | 3.90M | 3.72M |
| Net Income | -434,822,191 | 467.4K | 601.6K |
| Profit Margin | -14,394.0% | 12.0% | 16.2% |
| EBITDA | -434,805,484 | 1.16M | 1.10M |
| Free Cash Flow | — | 801.3K | 617.9K |
| Rev Growth | — | +18.2% | +4.0% |
| Debt/Equity | — | 0.89 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |